Harmony Biosciences Holdings (HRMY) Total Non-Current Liabilities (2019 - 2026)

Harmony Biosciences Holdings has reported Total Non-Current Liabilities for 8 years, with the latest figure at $144.1 million in Q1 2026.

• Quarterly Total Non-Current Liabilities fell 9.85% year-over-year to $144.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $144.1 million (down 9.85% YoY) and the FY2025 annual result came in at $149.3 million, down 9.51% from the prior year.
• Total Non-Current Liabilities fell to $144.1 million in Q1 2026 per HRMY's latest filing, from $149.3 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $193.0 million in Q1 2022 and troughed at $144.1 million in Q1 2026.
• A 5-year average of $173.3 million and a median of $177.3 million in 2024 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities rose 0.4% in 2022, then fell 11.97% in 2025.
• Over 5 years, Total Non-Current Liabilities stood at $192.1 million in 2022, then decreased by 5.97% to $180.7 million in 2023, then declined by 8.7% to $165.0 million in 2024, then retreated by 9.51% to $149.3 million in 2025, then slipped by 3.45% to $144.1 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $144.1 million, $149.3 million, and $149.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.